Clinical Trials Logo

Stem Cell Leukemia clinical trials

View clinical trials related to Stem Cell Leukemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04044560 Terminated - Clinical trials for Minimal Residual Disease

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

OZM-097
Start date: September 8, 2020
Phase: Phase 2
Study type: Interventional

This is a single arm, open label, multi-centre phase II study using blinatumomab for treatment of detectable minimal residual disease (MRD) in the first year following allogeneic hematopoietic stem cell transplant (HSCT) for patients with B cell acute lymphoblastic leukemia (B-ALL). The study has 2 phases: 1. MRD testing phase and 2. blinatumomab treatment phase. Participants with B-ALL planning for HSCT meeting other eligibility criteria will be enrolled onto the MRD testing phase, which will involve centralized MRD testing of bone marrow aspirate samples on day +56, +100, +180, +270 following HSCT. Participants with detectable MRD ≥10^-4 leukemic cells/total nucleated cells will enroll onto the treatment phase. Blinatumomab treatment will be started following detection of MRD after 7 to 42 days from enrollment onto the treatment phase to allow for initiation of taper of immunosuppressive medications.